We advised Oncopeptides on the private placement of shares

Davis Polk advised Oncopeptides AB (publ) on a private placement of new shares. The private placement raised gross proceeds of approximately SEK 1.1 billion ($130 million). 

Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company has recently been granted accelerated approval by the U.S. FDA for PEPAXTO (melphalan flufenamide, also known as melflufen), in relapsed or refractory multiple myeloma. Melphalan flufenamide is the first drug originated from the company’s proprietary PDC-platform and is evaluated in a comprehensive clinical study program, including the ongoing phase 3 OCEAN study. Oncopeptides’ global headquarters is in Stockholm, Sweden and the U.S. headquarters is situated in Boston, Massachusetts. The company is listed on Nasdaq Stockholm with the ticker ONCO.

The Davis Polk corporate team included partner Reuven B. Young and associate Serdar Inci. Counsel Alon Gurfinkel and associate Veronica Davis provided tax advice. All members of the Davis Polk team are based in the London office.

Copy link to share post